Navigation Links
Abt Bio-Pharma Solutions, Inc. Acquired by United BioSource Corporation

CAMBRIDGE, Mass., May 5 /PRNewswire/ -- Abt Associates announced today the sale of its wholly-owned subsidiary Abt Bio-Pharma Solutions, Inc. (ABS) to United BioSource Corporation (UBC), a global scientific and medical affairs organization that partners with life science companies to develop and commercialize biopharmaceuticals, medical devices, and other health care technologies. The addition of ABS scientists and resources establishes UBC with the largest presence and operational reach in the New England biomedical corridor and adds to its "best in class" portfolio of scientific and medical affairs solutions to support biopharmaceutical and medical technology companies.  

ABS was based in Lexington, Massachusetts and provided health economics and outcomes research, registries and observational studies, and market access solutions to the biopharmaceutical, medical device, and diagnostics industries. ABS originated in the early 1980s when Abt Associates' staff of biostatisticians, clinicians, health economists, and strategic consultants began designing, analyzing, and reporting on clinical trials for a broad variety of drugs and devices covering many therapeutic areas. It developed into the Abt Associates Clinical Trials division and in 2008 it was renamed and established as a wholly-owned subsidiary of Abt Associates.

Abt Associates President and Chief Executive Officer Kathleen Flanagan stated, "After building ABS into a respected player in its field, we are gratified to see our colleagues join a company that shares our values and can realize even greater potential. At UBC, there will be new resources and increased reach that translates into new opportunities for our clients to support their products."

"The scientists and capabilities that we gain with ABS are an excellent fit with our strategy," said Ethan Leder, CEO of United BioSource Corporation. With this acquisition UBC further expands its industry-leading team of senior experts in comparative effectiveness and comparative value; increases its registry and observational study practices; and reinforces its commercial strategy and market access capabilities.

Cain Brothers & Company, LLC acted as the financial advisor to Abt Associates in connection with transaction.

About Abt Bio-Pharma

Abt Bio-Pharma Solutions, Inc. (ABS) provides integrated clinical, health economic, and commercialization services to the pharmaceutical, biotechnology, medical device, and diagnostics industries worldwide. The company specializes in demonstrating the value, safety, and efficacy of health technologies through prospective studies as well as through retrospective data analyses, models, and quantitative and qualitative research. ABS teams of senior, seasoned staff help sponsors develop their research agendas, successfully conduct their research programs, and communicate the results to internal and external audiences. Primary service offerings include registries and other late-phase clinical studies, health economics and outcomes research, pricing and reimbursement, strategic commercialization services, and biometrics. For more information about ABS, visit

About United BioSource Corporation

United BioSource Corporation (UBC) is a global scientific and medical affairs organization that partners with life science companies to develop and commercialize biopharmaceuticals, medical devices, and other health care technologies. We help deliver authoritative, real-world evidence to characterize product effectiveness, address safety risk, and demonstrate value. UBC brings together recognized scientific and industry experts, research operations professionals, and new technologies to provide innovative solutions across the product lifecycle. The company is headquartered in Bethesda, Maryland, with offices in North and South America, Europe and Asia. For more information about UBC, visit

About Abt Associates

Abt Associates applies research, program implementation and technical assistance, and policy expertise to a wide range of social, economic and health policy issues; international development; and complex business problems.  Founded in 1965, the company provides services to U.S. federal, state and local governments; universities and foundations; media; and major corporations.  Its staff of over 1,500 is located in Cambridge, Massachusetts; Atlanta, Georgia; Bethesda, Maryland; Durham, North Carolina; New York, New York (Abt SRBI); and in Africa, Asia, Central Asia, Europe, Latin America, and the Middle East. For more information, visit

SOURCE Abt Associates
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Karen Walton-Bowen Joins Abt Bio-Pharma Solutions, Inc., as Senior Director, Biometrics
2. Bio-Pharma Industry Improves Patient Outcomes Through Continuing Medical Education (CME)
3. Huifeng Bio-Pharmaceutical (HFGB) Signs Exclusive Management Operating Agreement with Xian Qinba Xintong Medical Ltd.; HFGB to Retain Up to 70% of Qinbas Total Profit
4. Huifeng Bio-Pharmaceutical (HFGB) Enters into Letter of Intent with Xian Qinba Xintong Medical Ltd.
5. Huifeng Bio-Pharmaceutical (HFGB) to Attend CPhI South America 2008 Pharmaceutical Conference; The First CPhI Conference to be held in the Emerging Market of Brazil
6. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
7. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
8. Best Practice Database Supports Bio-Pharma Product Launch
9. Huifeng Bio-Pharmaceutical (HFGB) to Release Second Quarter 2008 Earnings Results on August 15, 2008
10. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on COS Application Status
11. Huifeng Bio-pharmaceutical Technology Inc. Announces Strategic Alliance with Premier Media Service Inc.
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... uBiome, were featured on AngelList early in their initial angel funding process. Now, ... syndicate for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... DIEGO , Nov. 24, 2015 Halozyme Therapeutics, Inc. ... Healthcare Conference in New York on Wednesday, ... Helen Torley , president and CEO, will provide a corporate ... New York at 1:00 p.m. ET/10:00 a.m. PT ... and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ - ... the request of IIROC on behalf of the Toronto ... this news release there are no corporate developments that ... price. --> --> ... --> . --> Aeterna Zentaris ...
(Date:11/24/2015)... ... ... The Academy of Model Aeronautics (AMA), led by its Executive Council, has officially ... to represent the First–Person View (FPV) racing community. , FPV racing has exploded in ... racing and several new model aviation pilots have joined the community because of their ...
Breaking Biology Technology:
(Date:11/18/2015)... PHILADELPHIA , Nov. 18, 2015  As new ... in children, doctors and other healthcare providers face challenges ... counsel families and patients. In addition, as more children ... into a patient,s adulthood and old age. ... The Children,s Hospital of Philadelphia (CHOP) . ...
(Date:11/17/2015)... 17, 2015 Paris ... --> Paris , qui s,est ... DERMALOG, le leader de l,innovation biométrique, a inventé le ... et empreintes sur la même surface de balayage. Jusqu,ici, ... l,autre pour les empreintes digitales. Désormais, un seul scanner ...
(Date:11/16/2015)... JOSE, Calif. , Nov 16, 2015 /PRNewswire/ ... developer of human interface solutions, today announced expansion ... Synaptics TouchView ™ touch controller and display ... architectural revolution of smartphones. These new TDDI products ... include TD4100 (HD resolution), TD4302 (WQHD resolution), and ...
Breaking Biology News(10 mins):